Search the Newsreel

PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk

PolyPid Ltd. reported an operating loss of $15.6 million and a net loss of $15.6 million for the first half of 2026, with cash and equivalents at $6.8 million, raising substantial doubt about its ability to continue as a going concern. Despite securing a …

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid Releases Q2 2026 Financial Results

PolyPid Ltd. reported a narrower-than-expected loss of $0.35 per share for Q2 2026, beating analyst estimates by 10.3%. The biopharmaceutical company posted a net loss of $7.8M as it advances its PLEX platform for targeted drug delivery. Analyst consensus remains bullish, with 7 buy …

PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

PolyPid (NASDAQ:PYPD) announced quarterly earnings of $(0.35) per share, surpassing analyst estimates by $0.03. Key developments include the FDA's priority review acceptance for D-PLEX100, a commercialization agreement with Azurity valued at $30 million upfront plus potential additional milestones, and an expected funding runway into …

PolyPid Q2 Earnings Call Highlights

Key Points Interested in PolyPid Ltd.? Here are five stocks we like better. FDA review advances: PolyPid's NDA for D-PLEX100 was accepted on July 27, 2026, with priority review and a Nov. 28 PDUFA target date. The company is preparing for a pre-approval manufacturing …

Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket

PolyPid Ltd. reported a narrowed Q2 2026 loss of $0.35 per share, exceeding analyst expectations, and highlighted significant progress with its Azurity Pharmaceuticals partnership and FDA priority review for D-PLEX100. Despite these positive developments, the stock fell 5.92% in premarket trading. The company anticipates …

PolyPid's D-PLEX100 Deal Includes Up to About $320M in Payments

PolyPid reported its Q2 2026 financial results, highlighting the FDA's acceptance of its D-PLEX100 NDA with Priority Review and a PDUFA goal date of November 28, 2026. The company also announced a commercialization agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, …

PolyPid (PYPD) secures D-PLEX100 FDA priority review and $30M Azurity deal

PolyPid Ltd. announced that the FDA granted Priority Review for its D-PLEX100 New Drug Application, setting a PDUFA goal date of November 28, 2026. Concurrently, PolyPid entered into an exclusive commercialization partnership with Azurity Pharmaceuticals for the U.S. and Canada, securing $30 million in …

PolyPid's Double Win: D-PLEX₁₀₀ Gains NDA Acceptance and Priority Review, Ahead of Schedule (NASDAQ: PYPD

PolyPid's D-PLEX₁₀₀, a drug candidate for preventing surgical site infections, has received New Drug Application (NDA) acceptance and Priority Review from the FDA, significantly shortening its target review timeline. This positive development comes shortly after PolyPid secured an exclusive commercialization partnership with Azurity Pharmaceuticals, …

PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026

PolyPid Ltd. announced it will release its second quarter 2026 financial results and operational highlights on August 12, 2026, before U.S. market opening, followed by a conference call and webcast at 8:30 AM ET. The company will discuss the successful Phase 3 SHIELD II …

PolyPid Schedules 8:30 a.m. Webcast for Aug. 12 Results

PolyPid (Nasdaq: PYPD) announced it will report Q2 2026 financial results and operational highlights on August 12, 2026, before U.S. markets open. Management will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update. …

PolyPid rises as lead product granted FDA priority review

PolyPid's stock increased by over 7% after the FDA granted priority review status for D-PLEX100, its lead product candidate. The FDA accepted PolyPid's New Drug Application for the Israeli biopharma company's product. This priority review indicates the potential for a faster approval process for …

PolyPid (PYPD) FDA Approvals, PDUFA Dates & Drug Alerts 2026

This article provides a detailed timeline of PolyPid's (PYPD) FDA-related milestones for its drug D-PLEX100, intended to prevent surgical site infections in colorectal surgery. Key events include the FDA's acceptance of the New Drug Application (NDA) with

PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review

PolyPid Ltd. (NASDAQ:PYPD) shares jumped over 11% after the FDA accepted its New Drug Application for D-PLEX100, granting it priority review for preventing surgical site infections in abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, which is …

FDA Acceptance Triggers $15M Payment to PolyPid Under Partnership

PolyPid Ltd. announced that the U.S. FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review, setting a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million milestone payment from Azurity Pharmaceuticals, completing $30 million in …

PolyPid (Nasdaq: PYPD) gets FDA Priority Review and $15M milestone

PolyPid Ltd. announced that the FDA has granted Priority Review for its New Drug Application (NDA) for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery, with a PDUFA target action date of November 28, 2026. This acceptance triggers a $15 million …

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid Ltd. announced that the FDA has accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review for the prevention of surgical site infections in abdominal colorectal surgery. The FDA set a PDUFA target action date of November 28, 2026, which is sooner …

PolyPid Ltd. Revenue Breakdown – NASDAQ:PYPD

This page from TradingView provides financial information for PolyPid Ltd. (NASDAQ: PYPD), including an overview of its financials, statements, statistics, dividends, earnings, and segment breakdown. It notes that the market is currently closed with no trades.

PolyPid Ltd (PYPD) Balance Sheet

This article provides a detailed balance sheet for PolyPid Ltd (PYPD), presenting quarterly and annual financial data dating back to 2013. It includes key financial metrics such as assets, liabilities, and shareholders' equity, allowing users to evaluate the company's financial health, liquidity, and leverage. …

PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for PolyPid Ltd (PYPD), focusing on volatility, financial risk, and investment risk. It presents various financial metrics including Beta, VaR, Maximum Drawdown, Volatility, and Sharpe Ratio over different time periods. The data indicates the stock's historical performance …

PolyPid Ltd (PYPD) Institutional Confidence

This article provides a brief overview of institutional confidence in PolyPid Ltd (PYPD), highlighting key institutional shareholders and their recent activity. It lists the number of shares held by major investors like Aurum Ventures M.K.I., Hodges (Rodney), Centaurus Investments Limited, and AIGH Capital Management, …

PolyPid, Azurity Sign US$330M Deal for D-PLEX100

PolyPid Ltd. and Azurity Pharmaceuticals have signed an exclusive deal worth up to US$330 million for the commercialization of D-PLEX100, an infection-prevention drug, in the U.S. and Canada. The agreement includes an upfront payment of US$15 million, potential milestone payments, and Azurity funding further …

TradingKey

This page from TradingKey provides the quarterly and annual income statements for PolyPid Ltd (PYPD). It details various financial metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income over several fiscal years and quarters. The article also includes FAQs …

PYPD|PolyPid Ltd|Price:3.900|Chg%:-0.340

PolyPid Ltd (PYPD) stock closed at $3.900, down 8.02% from its previous close. Analysts currently rate PYPD as a "Buy" with a target price of $12.00, suggesting a significant upside. The company is a biopharmaceutical firm focused on developing locally administered therapies for surgical …

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

PolyPid Ltd. (PYPD:NASDAQ) has entered into a commercialization agreement with Azurity Pharmaceuticals for its antibacterial drug, D-PLEX100, which aims to prevent surgical site infections. The deal provides PolyPid with an upfront payment of US$15 million, potential milestone payments up to US$300 million, and a …

H.C. Wainwright Maintains PolyPid(PYPD.US) With Buy Rating, Maintains Target Price $13

H.C. Wainwright has reaffirmed its Buy rating for PolyPid (PYPD.US) and maintained its target price of $13. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.

HC Wainwright Has Optimistic Outlook of PolyPid Q2 Earnings

H.C. Wainwright reiterates Buy on PolyPid stock, $13 target By Investing.com

H.C. Wainwright has reiterated its Buy rating and $13 price target for PolyPid (NASDAQ:PYPD) following a significant licensing agreement. PolyPid entered an exclusive licensing and collaboration agreement with Azurity Pharmaceuticals for D-PLEX100 in the U.S. and Canada, which includes $30 million upfront/near-term and potential …

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid has announced an exclusive commercial partnership with Azurity Pharmaceuticals for the U.S. and Canadian commercialization of D-PLEX₁₀₀, a drug designed to prevent surgical site infections. PolyPid stands to receive over $320 million in potential payments, including an initial $30 million upfront and near-term …

PolyPid - Eligible for up to $300 Mln in Addi

This article announces that PolyPid is eligible for up to $300 million in additional funding. The exact nature of this funding (e.g., grants, investments, milestone payments) is not detailed in the provided content. The brief title suggests a significant financial boost for the company.

PolyPid, Azurity sign surgical site infection drug deal

Israeli biotech PolyPid has signed a deal with Azurity Pharmaceuticals to commercialize its D-PLEX100 drug, aimed at preventing surgical site infections, in the U.S. and Canada. The agreement could bring PolyPid over $320 million, including an initial $15 million and potential milestone payments. PolyPid …

PolyPid's D-PLEX100 Shows 60% Lower Surgical Infection Risk in Phase 3

PolyPid has entered into an exclusive commercial partnership with Azurity Pharmaceuticals for its D-PLEX100 product in the U.S. and Canada, aimed at preventing surgical site infections. The deal, valued at over $320 million, includes upfront payments, milestones, and royalties, building on positive Phase 3 …

PolyPid signs $320M deal with Azurity for D-PLEX100 in U.S., Canada

PolyPid Ltd. announced an exclusive commercial partnership with Azurity Pharmaceuticals for D-PLEX100, aimed at preventing surgical site infections in the U.S. and Canada. The deal includes an upfront payment of $15 million, an additional $15 million upon FDA acceptance of the New Drug Application, …